drugset / Trial / NCT04401059
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Timeline
- Start
- 2020-11-09
- Primary completion
- 2025-09-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elemene | Traditional medicine (herbal / TCM) | 88 mg | Intravenous |
| Subject | Elemene | Traditional medicine (herbal / TCM) | 176 mg | Intravenous |
| Comparator | Almonertinib | Small molecule | — | — |
| Comparator | Erlotinib | Small molecule | — | — |
| Comparator | Firmonertinib | Small molecule | — | — |
| Comparator | Gefitinib | Small molecule | — | — |
| Comparator | Icotinib | Small molecule | — | — |
| Comparator | Osimertinib | Small molecule | — | — |